Asunercept (APG101)

October 2022

October 19, 2022

Apogenix’ Asunercept Demonstrates Efficacy in Phase II Trial for the Treatment of Hospitalized COVID-19 Patients

September 2017

“Apogenix and EMA to settle on Phase III plans for PRIME candidate asunercept” (Pink Sheet)
Article on Apogenix' negotiations with the EMA on the approval strategy for asunercept

May 2017

“German Checkpoint Inhibitor for Brain Cancer Prioritized by the EMA” (
Press coverage of the granting of the PRIME status for asunercept by the EMA

July 2016

“Phase 1 Pass for APG101” (Drug Discovery News)
Article on the phase I trial results with APG101 in patients with myelodysplastic syndromes

June 2016

“Apogenix’s Lead Candidate Has More than One Trick up its Sleeve” (
Report and interview (video) with Dr. Thomas Hoeger, CEO, about the development of APG101 for the treatment of glioblastoma and myelodysplastic syndromes

February 2016

Press coverage of the €3 million grant from the German Federal Ministry of Education for the clinical development of APG101 in combination with a companion diagnostic test:

July 2015

Press coverage of Apogenix’ cooperation with CANbridge for the development and commercialization of APG101 in Asia:

HERA-Ligands / TRAIL

May 2017

"AbbVie starts Phase I for TRAIL-receptor agonist in cancer" (BioCentury)
Report on the start of the first clinical trial with Apogenix' immuno-oncology candidate ABBV-621 (TRAIL receptor agonist) by AbbVie


June 2015

Peter Willinger Becomes CFO at Apogenix” (MedNous)
Report on Peter Willinger’s appointment as new CFO of Apogenix